Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

IV Lidocaine in Ortho Trauma Patients

9. november 2026 opdateret af: Jessica Phillips, Wayne State University

The Efficacy of Perioperative Intravenous Lidocaine as an Opioid Sparing Adjunct for Patients Undergoing Lower Extremity Orthopedic Trauma Surgery

In this research study, we will be evaluating whether an anesthesia provider using the method of intravenous lidocaine infusion during the perioperative and immediate postoperative period can provide equal short-term pain control and decrease postoperative opioid consumption compared to traditional opioid utilization. We will also evaluate the effects of intravenous lidocaine on inflammatory mediators such as interleukins and cytokines through timed lab draws. The study hypothesis is that intravenous lidocaine will provide similar pain relief and decrease the amount of post operative opioids used, as well as decrease the amount of inflammatory mediators present compared to conventional post-operative treatment utilizing solely opioids.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

66

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Michigan
      • Detroit, Michigan, Forenede Stater, 48201
        • Rekruttering
        • Detroit Receiving Hospital
        • Kontakt:
          • Jessica Phillips, PhD, CRNA
          • Telefonnummer: 313-577-9239
          • E-mail: fy9015@wayne.edu
        • Kontakt:
        • Ledende efterforsker:
          • Jessica Phillips, PhD, CRNA
        • Ledende efterforsker:
          • Mary Golinski, PhD, CRNA
        • Ledende efterforsker:
          • Wael Saasouh, MD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 85 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

- ASA physical status I-III, males and females >18 years of age and < 85 years of age, scheduled for repair of lower extremity (orthopedic) fracture/s of a single extremity. The type of injury will be documented and categorized- as applicable- in demographic data. The type of fracture will be extracted from the electronic surgical/operative report i.e. preoperative and postoperative diagnosis.

Exclusion Criteria:

  • Contraindication to lidocaine including allergy, substantial hepatic impairment (alanine aminotransferase greater than 120 IU/L or aspartate aminotransferase > 80 IU/L), substantial renal impairment (serum creatinine >2 mg/dL), current history of narcotic abuse, cognitive impairment (any patients who are alert and oriented x2 or less; for example, 0-2), cardiac ejection fraction less than 20% by documented cardiac consultation and evaluation, history of seizure disorders, and patients with documented sensory impairments such as neuropathies, fibromyalgia, and diabetes mellitus with concomitant neuropathies (because these sensory impairments may confound postoperative measurements of pain). Cardiac Ejection Fraction less than 20% further explained: Patients who are admitted to the hospital and scheduled for surgery that are deemed high cardiac risk (by history and physical and/or per patient) routinely have echocardiograms per standard of care, and if necessary further cardiac consultations and 'work ups' are performed at Detroit Receiving Hospital. With the thorough history and physical that is required, the results will be available prior to surgery and anesthesia. If a patient has demonstrated 'no cardiac risk factors' after a complete history and physical examination, they will be assumed to have a normal ejection fraction. Pregnant women will also be excluded as there have been no controlled studies in humans investigating the potential effects of intravenous lidocaine during pregnancy. All patients undergo a serum or urine HCG test prior to surgery, and these will be evaluated by the researchers.

Patients under the age of 18 will be excluded due to recent studies finding adverse reactions, although mild, appear to be common in children. Oxygen saturation of <95% on room air will be excluded per the lidocaine package insert. Weight of 150 kg (330 lbs) will be excluded per the lidocaine package insert.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Støttende pleje
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: Control Group - Saline Infusion

Saline bolus and infusion

Saline infusion

Eksperimentel: Intervention - IV Lidocaine Group

Lidocaine bolus and infusion

A Lidocaine (LID) bolus 2mg/kg followed by an infusion rate of 2 mg/kg/hr.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Morphine equivalents
Tidsramme: from enrollment to 14 days postoperative

Amount of opioids in morphine milligram equivalents (MME) used in 2 weeks/14 days postoperative period

from enrollment to 14 days postoperative
Interleukin 6 (IL-6)
Tidsramme: 1, 6, 24 and 48 hours postoperative

Interleukin 6 (IL-6) present in serum plasma at 1, 6, 24 and 48 hours postoperative in pg/mL

1, 6, 24 and 48 hours postoperative
Interleukin 8 (IL-8)
Tidsramme: 1, 6, 24 and 48 hours postoperative

Interleukin 8 (IL-8) present in serum plasma at 1, 6, 24 and 48 hours postoperative in pg/mL

1, 6, 24 and 48 hours postoperative
Complement C3a
Tidsramme: 1, 6, 24 and 48 hours postoperative

Complement C3a present in serum plasma at 1, 6, 24 and 48 hours postoperative in ng/mL

1, 6, 24 and 48 hours postoperative
Visual Analogue Pain Score
Tidsramme: Pain will be evaluated at 30-min intervals in post anesthesia care unit (PACU) and every 4 hr. thereafter up to 48 hour postoperative.

Visual Analogue Pain Score with 0 = no pain and 10 = worst pain ever.

Pain will be evaluated at 30-min intervals in post anesthesia care unit (PACU) and every 4 hr. thereafter up to 48 hour postoperative.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Quantitative Sensory Testing
Tidsramme: Postoperative day 1, day 3, and at the follow up first appointment with surgeon (approximately two weeks postoperatively)

Mechanical and thermal pain thresholds will be measured adjacent to the incision site to measure hyperalgesia

Postoperative day 1, day 3, and at the follow up first appointment with surgeon (approximately two weeks postoperatively)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

16. september 2026

Primær færdiggørelse (Anslået)

1. december 2027

Studieafslutning (Anslået)

1. december 2027

Datoer for studieregistrering

Først indsendt

9. november 2026

Først indsendt, der opfyldte QC-kriterier

9. november 2026

Først opslået (Faktiske)

16. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

9. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • IRB 24-11-7305
  • 2025-G-5 (Andet bevillings-/finansieringsnummer: AANA Foundation)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Any information containing patient information or protected health information (PHI) such as master list documents containing patient names and medical record numbers will be stored securely in a locked office inside a locked filing cabinet at the DMC site. All other data will use a subject number assigned and remove all 18 types of PHI information De-identified and be hard copies (paper records) will also be stored securely in a locked office inside a locked filing cabinet. DMC collected data will be saved on the DMC secure server in the Citrix platform. Study data will only be accessible to investigators involved in the study. Statistical analysis will be performed on de-identified encrypted digital data.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .